The obesity pipeline keeps getting more crowded, and the latest entrant is a name better known for brain drugs than metabolic ones. On August 7, Neurocrine Biosciences announced it had started a Phase 1 clinical trial for NBIP-1968 - a GLP-1/GIP/glucagon receptor triple agonist being developed for obesity.
It is early days. Phase 1 is where drugs first go into people, primarily to check safety, tolerability and how the body handles the drug. Many candidates never make it past this stage. But the announcement is a useful signal about where the field is heading, and it is worth understanding the context behind it.
What a “Triple Agonist” Is
To understand why NBIP-1968 matters, you need to understand the class. A triple agonist is a molecule designed to hit three receptors at once: GLP-1, GIP and glucagon.
GLP-1 is the receptor behind the weight-loss revolution - the target of semaglutide (Ozempic, Wegovy). GIP is the target of tirzepatide (Mounjaro, Zepbound), an incretin that plays its own role in glucose and fat metabolism. Glucagon is the third receptor, and adding it is where things get interesting, because glucagon signalling has effects on energy expenditure.
The most famous triple agonist in this space is retatrutide, Eli Lilly’s candidate, whose Phase 3 data put it above everything else on the market in terms of weight loss - averages in the range of 28% to 30%. The theory is that combining all three pathways produces weight loss that neither a single nor a dual agonist can match.
Neurocrine’s NBIP-1968 sits squarely in that class: a triple agonist taking aim at the same three receptors.
A Change of Direction for Neurocrine
The most notable thing about this announcement is who is making it. Neurocrine is not an obesity company. It is best known in neurology, largely through INGREZZA, its treatment in the tardive dyskinesia space. Its metabolic interest has been building, but this Phase 1 initiation marks a serious step into the obesity arena.
That pattern should look familiar. The past two years have seen a steady parade of companies - big pharma and smaller biotechs alike - pivot or expand into metabolic disease. The reason is straightforward: the commercial opportunity in obesity and GLP-1-class therapies is enormous, and it has drawn in everyone from established drugmakers to newer pipeline plays and oral small-molecule contenders.
Neurocrine’s move is consistent with that broader shift. Companies with deep drug-development expertise are betting that they can bring differentiated mechanisms to the obesity space rather than another copy of the existing drugs.
Where Triple Agonists Fit in the Pipeline
The triple agonist class is one of the most watched areas in the obesity pipeline, because it represents a genuine attempt to go beyond what current drugs achieve - not just a reformulation.
The excitement is driven by data. Retatrutide’s results have set a high bar, and other companies are working to match or differentiate against it. Earlier in the year, the field saw a steady stream of new candidates advancing, and ADA 2026 was dominated by the next-generation competitive picture - Lilly and Novo sharing the stage while a pack of challengers looked for openings.
The key question for any triple agonist is whether the added glucagon component delivers meaningfully better outcomes, and whether its side-effect profile - glucagon agonism can come with its own tolerability trade-offs - stays manageable. That is exactly what the coming clinical readouts will test.
Why Phase 1 Still Matters
It is easy to dismiss a Phase 1 start as noise in an already crowded field. But it is worth being precise about what a Phase 1 announcement does and does not tell you.
What it tells you: a company has committed resources, believes the compound is worth putting into people, and has cleared the preclinical hurdles. It is a real technical milestone - the drug has survived animal work and is now being tested for safety and tolerability in humans.
What it does not tell you: whether the drug works, whether it will be differentiated, or whether it will ever reach patients. Most Phase 1 candidates fail. For a triple agonist specifically, the bar is high, because the class already has a strong incumbent (retatrutide) and the market is full of well-funded competitors.
So NBIP-1968’s Phase 1 start is worth noting as a data point about the direction of the field, not as a reason to expect a new blockbuster soon. It is research interest at a very early stage.
What the Research Says
The relevant research context for NBIP-1968 is the broader evidence on triple agonism:
- Retatrutide’s Phase 3 programme demonstrated weight loss exceeding that of all commercially available incretin therapies, supporting the potential of combined GLP-1/GIP/glucagon activation.
- The class is at an early stage for most entrants, with Phase 1 and Phase 2 candidates across multiple companies.
- The scientific case for adding glucagon agonism rests on its effects on energy expenditure, but tolerability and long-term outcomes remain open questions for the class.
The jury is out on NBIP-1968 specifically, and likely will be for years. What the announcement confirms is that triple agonism has become a mainstream bet in obesity R&D, and Neurocrine wants a seat at that table.
The Bottom Line
Neurocrine’s entry into the triple agonist space is a small but telling sign of how the obesity landscape is shaping up. More companies, more mechanisms, more capital - all chasing the same problem, and most will not make it. But the compounding of interest in the class is itself a signal that triple agonism is one of the most actively pursued ideas in modern metabolic research.
For the latest on new compounds and the obesity pipeline, jump into the Grey Highway Telegram community.
Disclaimer: This article is for educational and informational purposes only. It does not constitute medical advice, therapeutic recommendations, or endorsements of any compound. Grey Highway is a research-education community. We do not sell, supply, or promote the use of research compounds. Always consult a qualified healthcare professional regarding health decisions. For Australian regulatory information, visit the TGA website.
Sources:
- PR Newswire (August 7, 2026) - “Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist”
- Clinical Trials Arena (August 10, 2026) - “Neurocrine begins Phase I trial of NBIP-1968 triple agonist for obesity”
- BioPharm International (August 7, 2026) - “Neurocrine Biosciences Begins Phase 1 Study of GLP-1/GIP/Glucagon Triple Agonist NBIP-1968 for Obesity”
- AllSci (August 7, 2026) - “Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study”
- Investing.com (August 7, 2026) - “Neurocrine starts phase 1 trial of obesity drug candidate”